Suppr超能文献

糖尿病合并慢性肾脏病患者的血清总蛋白与白蛋白比值及不良临床结局:美国和中国队列的比较研究

Serum total protein-to-albumin ratio and adverse clinical outcomes in patients with diabetes and chronic kidney disease: a comparative study of US and Chinese cohorts.

作者信息

Lang Yanlin, Zou Yutong, Liu Ke, Yuan Jiamin, Yang Qing, Liu Fang

机构信息

Department of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.

Laboratory of Diabetic Kidney Disease, Department of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Int Urol Nephrol. 2025 Aug 6. doi: 10.1007/s11255-025-04673-1.

Abstract

OBJECTIVE

This study aimed to explore the predictive value of serum total protein-to-albumin ratio (TAR) for all-cause mortality and other adverse clinical outcomes in patients with diabetes mellitus (DM) and chronic kidney disease (CKD).

METHODS

Data were obtained from two cohorts: 1628 patients with DM and CKD in cohort 1 from the National Health and Nutrition Examination Survey and 341 renal biopsy-confirmed diabetic nephropathy (DN) patients in cohort 2 from West China Hospital of Sichuan University. Patients were grouped by the TAR levels. TAR was calculated as serum total protein divided by albumin. The primary outcome was all-cause mortality. Cox proportional hazards regression assessed associations between TAR and adverse clinical outcomes, adjusting for demographic, clinical, and laboratory variables. Stratification, interaction, and correlation analyses were performed.

RESULT

In cohort 1, higher TAR independently increased all-cause and cardiovascular mortality risk (HR 1.60, 95% confidence interval (CI) 1.18-2.17, HR 1.97, 95% CI 1.09-3.58, respectively). Subgroup analyses showed significant association between TAR and all-cause mortality in participants with albumin creatinine ratio (ACR) < 30 mg/g (HR 2.34, 95% CI 1.15-4.75), with an interaction observed for ACR (P for interaction = 0.048). Patients in the high TAR group with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m had higher risk of cardiovascular mortality (HR 2.56, 1.1-5.98), with an interaction observed for eGFR (P for interaction = 0.018). In cohort 2, higher TAR was associated with risk of all-cause mortality and progression to ESRD in the univariate analysis (HR 2.46, 95% CI 1.18-5.11, HR 2.02, 95% CI 1.47-2.79, respectively). After adjustments, point estimates of HR decreased and 95%CI narrowed. TAR was positively correlated with systolic blood pressure, proteinuria, creatinine, renal pathological classification, renal interstitial fibrosis and tubular atrophy, and interstitial inflammation, while negatively correlated with eGFR, total protein, albumin, and hemoglobin.

CONCLUSION

Higher TAR was associated with increased all-cause and cardiovascular mortality in DM and CKD patients. Clinicians can use TAR to better stratify risk and guide treatment, improving outcomes.

摘要

目的

本研究旨在探讨血清总蛋白与白蛋白比值(TAR)对糖尿病(DM)合并慢性肾脏病(CKD)患者全因死亡率和其他不良临床结局的预测价值。

方法

数据来自两个队列:队列1为1628例来自美国国家健康与营养检查调查的DM合并CKD患者,队列2为341例来自四川大学华西医院经肾活检确诊的糖尿病肾病(DN)患者。患者按TAR水平分组。TAR计算为血清总蛋白除以白蛋白。主要结局为全因死亡率。Cox比例风险回归评估TAR与不良临床结局之间的关联,并对人口统计学、临床和实验室变量进行校正。进行了分层、交互作用和相关性分析。

结果

在队列1中,较高的TAR独立增加全因和心血管疾病死亡风险(风险比分别为1.60,95%置信区间(CI)1.18 - 2.17;1.97,95%CI 1.09 - 3.58)。亚组分析显示,在白蛋白肌酐比值(ACR)<30 mg/g的参与者中,TAR与全因死亡率之间存在显著关联(风险比2.34,95%CI 1.15 - 4.75),观察到ACR存在交互作用(交互作用P值 = 0.048)。估算肾小球滤过率(eGFR)<60 mL/min/1.73m²的高TAR组患者心血管疾病死亡风险更高(风险比2.56,1.1 - 5.98),观察到eGFR存在交互作用(交互作用P值 = 0.018)。在队列2中,单因素分析显示较高的TAR与全因死亡率和进展至终末期肾病的风险相关(风险比分别为2.46,95%CI 1.18 - 5.11;2.02,95%CI 1.47 - 2.79)。校正后,风险比的点估计值下降,95%CI变窄。TAR与收缩压、蛋白尿、肌酐、肾脏病理分类、肾间质纤维化和肾小管萎缩以及间质炎症呈正相关,而与eGFR、总蛋白、白蛋白和血红蛋白呈负相关。

结论

较高的TAR与DM合并CKD患者全因和心血管疾病死亡率增加相关。临床医生可使用TAR更好地分层风险并指导治疗,改善结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验